| Citation: |
LI Hao, BAO Xiaqing, LIU Xianju. Efficacy and safety of icotinib in treating patients with advanced esophageal squamous cell carcinoma in failure of first-line chemotherapy[J]. Journal of Clinical Medicine in Practice, 2022, 26(13): 105-109. DOI: 10.7619/jcmp.20215138
|
To explore the efficacy and safety of icotinib as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in treating patients with advanced esophageal squamous cell carcinoma (ESCC) in failure of first-line chemotherapy.
A total of 58 advanced ESCC patients failed to first-line chemotherapy (treatment of platinum combined with paclitaxel or fluorouracil) in the Department of Oncology of Affiliated Hospital of Qinghai University from October 2017 to January 2020 were selected as research objects, and the objective response rate (ORR), disease control rate (DCR) and adverse reactions of orally taken of icotinib were analyzed. Kaplan-Meier survival curve was used to calculate the progression free survival (PFS) and overall survival (OS).
Among the 58 advanced ESCC patients with icotinib therapy, 4 cases (6.9%) achieved complete remission (CR), 20 cases (34.5%) achieved partial remission (PR), 21 cases (36.2%) achieved stable disease (SD), and 13 cases (22.4%) developed into tumor progression (PD); the ORR and DCR were 41.4% (24/58) and 77.6% (45/58) respectively. The median PFS was 5.6 months (95%CI, 1.6 to 9.6) and the median OS was 18.5 months (95%CI, 10.2 to 26.8). Fatigue (34.5%), nausea and vomiting (29.3%) and diarrhea (20.7%) were the most common adverse reactions during treatment.
Icotinib has good therapeutic effect and safety in treating advanced ESCC patients failed to first-line chemotherapy, which may delay tumor progression and further improve the survival benefit of patients.
| [1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA a Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
|
| [2] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA a Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [3] |
FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22. doi: 10.1186/s40880-019-0368-6
|
| [4] |
刘曙正, 于亮, 陈琼, 等. 2003—2012年食管癌高发区林州市不同病理类型食管癌发病及生存状况分析[J]. 中华预防医学杂志, 2017, 51(5): 393-397. doi: 10.3760/cma.j.issn.0253-9624.2017.05.005
|
| [5] |
LIN Y, TOTSUKA Y, HE Y, et al. Epidemiology of esophageal cancer in Japan and China[J]. J Epidemiol, 2013, 23(4): 233-242. doi: 10.2188/jea.JE20120162
|
| [6] |
LEE S J, KIM S, KIM M, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase Ⅱ study[J]. BMC Cancer, 2015, 15: 693. doi: 10.1186/s12885-015-1716-9
|
| [7] |
YAMASAKI M, YASUDA T, YANO M, et al. Multicenter randomized phase Ⅱ study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)[J]. Ann Oncol, 2017, 28(1): 116-120. doi: 10.1093/annonc/mdw439
|
| [8] |
FANG M, SONG T, LIANG X D, et al. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma[J]. Oncotarget, 2017, 8(23): 37080-37090. doi: 10.18632/oncotarget.16180
|
| [9] |
NISHIMURA Y, HIRAOKA M, KOIKE R, et al. Long-term follow-up of a randomized Phase Ⅱstudy of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021)[J]. Jpn J Clin Oncol, 2012, 42(9): 807-812. doi: 10.1093/jjco/hys112
|
| [10] |
HONG L, HAN Y, BRAIN L. Epidermal growth factor receptor: an important target in esophageal cancer[J]. Expert Opin Ther Targets, 2013, 17(10): 1179-1185. doi: 10.1517/14728222.2013.820709
|
| [11] |
SHARMA B, SINGH V J, CHAWLA P A. Epidermal growth factor receptor inhibitors as potential anticancer agents: an update of recent progress[J]. Bioorg Chem, 2021, 116: 105393. doi: 10.1016/j.bioorg.2021.105393
|
| [12] |
HE J, SU C, LIANG W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial[J]. Lancet Respir Med, 2021, 9(9): 1021-1029. doi: 10.1016/S2213-2600(21)00134-X
|
| [13] |
XU L, QI Q, ZHANG Y, et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study[J]. Lung Cancer, 2019, 133: 23-31. doi: 10.1016/j.lungcan.2019.05.008
|
| [14] |
LI X, ZHANG L, DA J, et al. Routine-dose and high-dose icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21-L858R mutation: the randomized, phase II, INCREASE trial[J]. Clin Cancer Res, 2020, 26(13): 3162-3171. doi: 10.1158/1078-0432.CCR-19-3064
|
| [15] |
EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
|
| [16] |
TROTTI A, COLEVAS AD, SETSER A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol, 2003, 13(3): 176-181. doi: 10.1016/S1053-4296(03)00031-6
|
| [17] |
KOTECKI N, HIRET S, ETIENNE P L, et al. First-line chemotherapy for metastatic esophageal squamous cell carcinoma: clinico-biological predictors of disease control[J]. Oncology, 2016, 90(2): 88-96. doi: 10.1159/000442947
|
| [18] |
HIRAMOTO S, KATO K, SHOJI H, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2018, 23(3): 466-472. doi: 10.1007/s10147-018-1239-x
|
| [19] |
SHALATA W, JACOB B M, AGBARYA A. Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future[J]. Cancers (Basel), 2021, 13(16): 14754.
|
| [20] |
MOK T S, CHENG Y, ZHOU X D, et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J]. Drugs, 2021, 81(2): 257-266. doi: 10.1007/s40265-020-01441-6
|
| [21] |
XIE C, JING Z, LUO H, et al. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial[J]. Br J Cancer, 2020, 123(11): 1616-1624. doi: 10.1038/s41416-020-01054-6
|
| [22] |
石远凯, 孙燕, 丁翠敏, 等. 中国埃克替尼治疗非小细胞肺癌专家共识(2015版)[J]. 中国肺癌杂志, 2015, 18(7): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201507001.htm
|
| [23] |
ZENG Z, YAN B, CHEN Y, et al. Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study[J]. Transl Lung Cancer Res, 2020, 9(6): 2401-2410. doi: 10.21037/tlcr-20-1214
|
| [24] |
LIANG S, XU Y, TAN F L, et al. Efficacy of icotinib in advanced lung squamous cell carcinoma[J]. Cancer Med, 2018, 7(9): 4456-4466. doi: 10.1002/cam4.1736
|
| [25] |
LIU K, JIANG G, ZHANG A, et al. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer[J]. BMC Cancer, 2020, 20(1): 76. doi: 10.1186/s12885-020-6543-y
|
| [26] |
LIU Y, ZHANG Y, FENG G, et al. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis[J]. Exp Ther Med, 2017, 14(5): 4017-4032.
|
| [27] |
SHI Y, ZHANG L, LIU X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10): 953-961. doi: 10.1016/S1470-2045(13)70355-3
|
| [28] |
HUANG J, FAN Q, LU P, et al. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study[J]. J Thorac Oncol, 2016, 11(6): 910-917. doi: 10.1016/j.jtho.2016.02.020
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: